A study to evaluate the excretory dynamics of intestinal fluorodeoxyglucose(FDG) by metformin using continuous imaging of 18F-FDG-PET/MRI
Not Applicable
- Conditions
- patients with type 2 diabetes
- Registration Number
- JPRN-UMIN000043446
- Lead Sponsor
- Kobe university
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 5
Inclusion Criteria
Not provided
Exclusion Criteria
(1) Patients who participated in other clinical trials within 3 months prior to obtaining consent (2) Patients suffering from dementia or mental illness (3) Patients with possible bowel perforation or obstruction (4) Patients with metals in the body that are not amenable to PET/MRI testing (5) Pregnant or breast feeding patients (6) Other patients who are deemed inappropriate by the investigators of this clinical study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method site of excretion pathway in the intestinal tract of fluorodeoxyglucose(FDG)
- Secondary Outcome Measures
Name Time Method Clinical parameters of HbA1c, blood glucose level, biochemical test items, background factors of study subjects